Global Digital Therapeutics for Diabetes Market - 2024-2031

The global digital therapeutics for diabetes market reached US$ 1.6 billion in 2023 and is expected to reach US$ 5.3 billion by 2033, growing at a CAGR of 12.9% during the forecast period 2025-2033.

Digital therapeutics for diabetes refers to a category of evidence-based, software-driven solutions designed to prevent, manage or treat diabetes, leveraging digital technology, behavioral science and personalized data. These solutions are intended to be used either as stand-alone therapies or in conjunction with traditional treatments such as medications and insulin. They aim to help patients manage their condition by addressing the root causes of diabetes, such as lifestyle factors, medication adherence and glucose regulation, through real-time monitoring, behavior modification and patient education.

The demand for digital therapeutics for diabetes is experiencing significant growth, driven by the increasing prevalence of diabetes and the need for continuous disease management. This growth is primarily fueled by the rising adoption of smartphones and digital health technologies, which provide cost-effective, scalable and personalized management solutions for chronic diseases like diabetes. For instance, according to the Peterson Health Technology Institute (PHTI), the economic impact on purchasers of digital diabetes management solutions depends on the price of the digital solution and how it affects patterns of healthcare utilization and spending for patients who use them. It assumes a 25% adoption rate among eligible users.

Market Dynamics: Drivers & Restraints

Rising prevalence of diabetes

The rising prevalence of diabetes is significantly driving the growth of the digital therapeutics for diabetes market and is expected to drive the market over the forecast period, as the increasing number of people diagnosed with diabetes necessitates new, scalable and effective treatment options. Digital therapeutics are seen as an efficient way to manage diabetes, especially with the growing demand for remote care, personalized treatment plans and real-time monitoring.

For instance, according to the International Diabetes Federation, in 2021, 536.6 million adults (20-79 years) are living with diabetes i.e., 1 in 10 people. This number is predicted to rise to 642.8 million by 2030 and 783.7 million by 2045. Over 3 in 4 adults with diabetes live in low- and middle-income countries. Diabetes is responsible for 6.7 million deaths in 2021 - 1 every 5 seconds. 541 million adults have Impaired Glucose Tolerance (IGT), which places them at high risk of type 2 diabetes. This escalating prevalence highlights the urgent need for accessible and cost-effective diabetes management solutions.

Diabetes is a chronic condition requiring lifelong management and digital therapeutics provide a means to continuously monitor and adjust treatment plans. Digital platforms and connected devices, like continuous glucose monitors (CGMs), mobile apps, and insulin dose trackers, offer real-time data, allowing for more personalized care. This is particularly useful for the Type 1 and Type 2 diabetes populations, where adherence to treatment plans is crucial.

For instance, BlueStar (powered by Welldoc), a digital therapeutic solution for diabetes management, integrates with insulin dosing recommendations and continuous glucose monitoring to provide personalized guidance, demonstrating the growing importance of digital therapeutics in day-to-day diabetes management.

Data privacy concerns

Data privacy concerns are a significant barrier to the growth of digital therapeutics for the diabetes market, as they directly impact trust, adoption rates and regulatory compliance. Digital therapeutics involve the collection and processing of sensitive health data, such as glucose levels, insulin doses and lifestyle habits, which raises concerns regarding the security, storage and sharing of this information.

Digital health platforms for diabetes management often require users to input personal health information, including real-time data from devices like continuous glucose monitors (CGMs) or smart insulin pens. This data, being highly sensitive, must be handled with the utmost care to avoid breaches that could expose personal health information.

For instance, according to the HIPAA Journal, in August 2023, 23 million breached healthcare records are noticed. Over the past 12 months, an average of 9,989,003 healthcare records were breached each month. In the year to August 31, 2024, there have been 491 data breaches of 500 or more records, and at least 58,668,002 records are known to have been breached. The average breach size in 2024 is currently 119,487 records and the median breach size is 4,109 records.

Segment Analysis

The global digital therapeutics for diabetes market is segmented based on product type, application, end-user and region.

Product Type:

The software solutions segment is expected to dominate the digital therapeutics for diabetes market share

The software solutions segment is expected to dominate the global digital therapeutics for diabetes market. Software-based solutions such as mobile apps and digital platforms allow patients to track glucose levels, insulin use, diet and physical activity, providing personalized feedback and treatment recommendations. For instance, in November 2024, PureHealth revealed a huge surge in users of Pura, the group's AI-enabled app. With over 140,000 downloads to date, Pura aims to improve quality of life and lifespans by providing individuals with personalized data, empowering them to improve their health through user-friendly tools and tailored insights.

Mobile and web-based applications are easy to use and accessible for a wide range of patients, including those in rural or underserved areas. The growing smartphone penetration is a key factor in this segment's dominance. For instance, in November 2023, Abbott launched its digital health tool, FreeStyle LibreLink app in India. The mobile app allows people who use the FreeStyle Libre system to measure their glucose readings on their mobile phones without pricking. The mobile app is compatible with iPhone and Android smartphones.

The integration of digital therapeutics software with wearable devices like continuous glucose monitors and smart insulin pens allows for seamless, continuous monitoring of diabetes. These integrations are essential for patients with Type 1 and Type 2 diabetes, who need real-time adjustments to their insulin and lifestyle. As mentioned above, Abbott's Freestyle Libre, connects with mobile apps to provide real-time glucose tracking, demonstrating the growing adoption of software solutions in diabetes management.

Geographical Analysis

North America is expected to hold a significant position in the digital therapeutics for diabetes market share

North America is expected to hold the largest market share in the global digital therapeutics for diabetes market. North America, particularly the United States, has a high diabetes prevalence, which fuels the demand for digital therapeutics solutions. For instance, according to the Centers for Disease Control and Prevention (CDC), In 2021, 29.7 million people of all ages or 8.9% of the U.S. population had been diagnosed with diabetes and the number is expected to rise as the population ages. This includes 304,000 with type 1 diabetes. 3.6 million adults aged 20 years or older or 12.3% of all U.S. adults with diagnosed diabetes and started using insulin within a year of their diagnosis.

The United States has one of the highest rates of smartphone and internet penetration globally, making it an ideal market for the adoption of digital health solutions like mobile apps and wearable devices. This technological infrastructure is pivotal for the adoption of digital therapeutics platforms that require constant connectivity for real-time data sharing and analysis. For instance, new National Telecommunications and Information Administration (NTIA) data showed 13 million more internet users in the U.S. in 2023 than in 2021.

Digital health solutions like Welldoc's BlueStar and Omada Health's digital platform for diabetes management have gained significant traction in the U.S., further solidifying North America's leadership in the space.

Asia-Pacific is growing at the fastest pace in the digital therapeutics for diabetes market

The Asia-Pacific region is experiencing the fastest growth in the digital therapeutics for diabetes market. There is a strong push towards digital health and telemedicine in countries like India, China and Australia, where smartphone penetration is rapidly increasing.

For instance, India had over 700 million active internet users aged 2 years and above as of December 2022, according to Nielsen's India Internet Report 2023. Of these, rural India accounted for 425 million users, which was almost 44% higher than the number of active internet users in urban areas, with 295 million users, providing a strong foundation for the growth of mobile-based digital therapeutics platforms.

Several APAC countries have launched initiatives to support digital health technologies. For example, China's "Healthy China 2030" plan aims to enhance healthcare infrastructure, which includes the adoption of digital health tools for chronic disease management.

Competitive Landscape

The major global players in the digital therapeutics for diabetes market include Welldoc, Inc., Omada Health Inc., Glooko, Inc., Azumio Inc., Abbott Laboratories, mySugr GmbH, Dexcom, Inc., Health2Sync, iHealth Labs Inc., Medtronic plc and among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global digital therapeutics for diabetes market report delivers a detailed analysis with 62 key tables, more than 52 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.